MAPT Gene Mutation clinical trials at UCSF

1 research study open to eligible people

A MAPT gene mutation is a change in the gene related to brain health. UCSF is examining how these mutations contribute to diseases like frontotemporal lobar degeneration through clinical trials. These studies provide valuable insights into the disease.

Showing trials for

  • ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

    open to eligible people ages 18 years and up

    ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

    San Francisco, California and other locations

Our lead scientists for MAPT Gene Mutation research studies include .

Last updated: